NOTE: This material is cited in a U.S. and/or other Patent and may not be used to infringe the patent claims.
Sexually Transmitted Disease Research
Biosafety Level
2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.
Isolation
Crossing of parental strains of HSV-1 (HFEMtsN102) and HSV-2 (186)
Product Format
freeze-dried
Storage Conditions
-60°C or colder
Disclosure
This material is cited in a US or other Patent and may not be used to
infringe the claims. Depending on the wishes of the Depositor, ATCC may be
required to inform the Patent Depositor of the party to which the material was
furnished. This material may not have been produced or characterized by ATCC.
Comments
Avirulent. Provides immunity to massive challenges of wild type strains of both HSV-1 and HSV-2. Low pathogenicity. NOTE: This material is cited in a U.S. and/or other Patent and may not be used to infringe the patent claims.
Effect on Host
Cytopathic effects in tissue culture
Recommended Host
HEp-2 cells (ATCC CCL-23); Vero cells (ATCC CCL-81)
HEp-2 cells (ATCC CCL-23); Vero cells (ATCC CCL-81)
Crossing of parental strains of HSV-1 (HFEMtsN102) and HSV-2 (186)
References
Roizman B, Lang MR. Vaccine and method of immunizing against herpes simplex virus (types 1 and 2). US Patent 4,554,159 dated Nov 19 1985
Morse LS, et al. Anatomy of herpes simplex virus DNA. IX. Apparent exclusion of some parental DNA arrangements in the generation of intertypic (HSV-1 X HSV-2) recombinants. J. Virol. 24: 231-248, 1977. PubMed: 198577
